0
Skip to Content
Celea Therapeutics
Home
Deupirfenidone
Clinical Data
Patient Experience
About
Celea Therapeutics
Home
Deupirfenidone
Clinical Data
Patient Experience
About
Home
Deupirfenidone
Clinical Data
Patient Experience
About
Sven Dethlefs, PhD
Jamison Wright 6/9/26 Jamison Wright 6/9/26

Sven Dethlefs, PhD

Chief Executive Officer

Read More
David Golod, PhD, MBA
Jamison Wright 6/9/26 Jamison Wright 6/9/26

David Golod, PhD, MBA

Clinical Operations & Program Strategy

Read More
Camilla Graham, MD, MPH
Jamison Wright 6/9/26 Jamison Wright 6/9/26

Camilla Graham, MD, MPH

Medical Affairs

Read More
Neera Jain, PhD, MBA
Jamison Wright 6/8/26 Jamison Wright 6/8/26

Neera Jain, PhD, MBA

Chemistry, Manufacturing, and Controls

Read More

Contact

info@celeatx.com

Resources

Download Deupirfenidone Presentation (PDF)

Press Releases

Publication

The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether deupirfenidone is safe and effective. No regulatory agency has made any such determination that deupirfenidone is safe or effective for use by the general public for any indication.